Chemotherapy
Positive Interim Results from Global Phase III MATTERHORN Study: Imfinzi plus FLOT Demonstrates Clinically Meaningful Improvement in Key Secondary Endpoint (ESMO 2023)
ESMO 2023: LBA73 The results of a MATTERHORN trial was presented in ESMO 2023. The trial tested the effect of ...
National Cancer Group Raises Alarm Over Persistent Chemo Shortage Despite FDA’s Vigilant Efforts
Despite recent efforts by the White House and the FDA to address the chemotherapy shortage in the United States, a ...
Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)
Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...
Amgen Unveils Exciting First-Line KRAS G12C NSCLC Data: Lumakras (Sotorasib) with Chemotherapy Shines at WCLC
Amgen has unveiled exciting findings from a segment of the CodeBreaK 101 clinical trial, a Phase 1b study investigating the ...
Cervical Cancer: Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity
The combination of the novel bifunctional fusion protein SHR-1701 with bevacizumab (BP102) and platinum-doublet chemotherapy has shown promising results in ...
Positive Effects of Rybrevant Plus Chemotherapy in Early EGFR Exon 20 Insertion NSCLC
Source – Johnson & Johnson The combination of amivantamab-vmjw (Rybrevant) with the chemotherapy doublet carboplatin and pemetrexed has demonstrated a ...
Despite a lack of essential cancer medications, the FDA approves additional chemotherapy imports from China’s Qilu Pharmaceutical
The ongoing shortage of crucial chemotherapy drugs in the United States has led the FDA to import a supply from ...
In unresectable/metastatic urothelial carcinoma, upfront nivolumab/chemotherapy prolongs survival
Source –Bristol-Myers Squibb Nivolumab plus chemotherapy showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival ...
Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression
First-line treatment with pembrolizumab (Keytruda) has demonstrated long-term survival benefits and durable responses in patients with PD-L1-positive, locally advanced or ...
Combining mitazalimab with chemotherapy demonstrates significant antitumor activity in metastatic pancreatic ductal adenocarcinoma
Source – Alligator Bioscience On June 26, 2023 the combination of mitazalimab, a novel CD40 monoclonal antibody agonist, with chemotherapy ...
Stem Cell Transplant: A Definitive Insight
Introduction Stem cell transplant, also known as bone marrow transplant, is a procedure that can save the lives of people ...
DEMYSTIFYING MYELOFIBROSIS SYMPTOMS: A Closer Look
Introduction: Myelofibrosis symptoms Myelofibrosis is a rare and serious blood cancer that affects the bone marrow, the soft tissue inside ...
Understanding Myelofibrosis Treatment: What You Need to Know
Introduction: Myelofibrosis Treatments In this article, we will discuss some of the most common Myelofibrosis treatments and what to expect ...
